BioMarin Quantifies Alesta Acquisition Charges: ~$320M Pre-Tax Hit, ~$1.55 EPS Drag for 2026
BMRN is trading near its 52-week low of $49.259 (14% above the low) on elevated volume (1.9× avg).
Summary
BioMarin quantified the financial impact of its Alesta Therapeutics acquisition: ~$283M Q3 IPR&D charge, ~$320M full-year pre-tax charges, and ~$1.55 EPS drag for 2026. The Alesta acquisition closed in early September. Updated guidance will come with Q3 results.
Updated with a Dow Jones Newswires report · What changed
Updates
· Dow Jones Newswires — BioMarin expects $283 million in pre-tax charges in Q3 from its Alesta acquisition, closed in early September.
Key Events · Earnings and Guidance · BMRN
-
Updated · · Dow Jones Newswires
Alesta Acquisition Charges Quantified
BioMarin expects ~$283M pre-tax acquired IPR&D expense in Q3 2026 and ~$320M total pre-tax charges for full-year 2026 related to the Alesta Therapeutics acquisition, which closed in early September.
-
EPS Impact Disclosed
The charges represent an unfavorable impact of ~$1.50 to Q3 diluted EPS and ~$1.55 to full-year 2026 diluted EPS, on both GAAP and non-GAAP bases.
-
Prior Guidance Did Not Include Deal
BioMarin's full-year 2026 guidance announced August 6, 2026 did not reflect the Alesta acquisition; updated guidance will be provided with Q3 2026 results.
-
Preliminary Estimates Subject to Change
Q3 results are not finalized and actual results may differ from these preliminary estimates.
Analysis · BMRN · Life Sciences
BioMarin disclosed that its Alesta Therapeutics acquisition, which closed in early September, will generate approximately $283 million in acquired in-process R&D expense in Q3 2026 and roughly $320 million in total pre-tax charges for the full year, translating to an unfavorable impact of about $1.50 per share in Q3 and $1.55 per share for 2026 on both GAAP and non-GAAP diluted EPS. The company's prior full-year guidance did not include these charges, so investors should expect a downward revision when Q3 results are reported. This is a material quantification of a previously announced deal, not a new acquisition.
How filings like this one have moved
In the 30 days to Nov 6, 2026, 35.2% of the 2649 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BMRN was trading at $56.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.9B. The 52-week trading range was $49.26 to $70.98. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.